Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs

Kohei Takata; Stephen J. Nicholls


Am J Cardiovasc Drugs. 2019;19(2):113-131. 

In This Article


Despite the residual risk in the statin era, the approach of LDL-C lowering has been established as the cornerstone for ASCVD prevention. While 36% of subjects receiving the combination of a statin and evolocumab experienced disease progression in the GLAGOV trial, success with PCSK9 inhibitors would reinforce LDL-C–lowering therapies and the use of genetics to identify additional therapeutic gene targets. Given the causal role of TRLs in ASCVD, the results of ongoing CVOTs in optimally designed populations investigating omega-3 fish oils and SPPARMα are awaited. Although novel therapeutic approaches, especially non-oral medications, may be limited in future clinical applications because of their cost-effectiveness despite their beneficial effects, a new era of ASCVD prevention is almost here.